1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

BMS finalises Amylin buy, Lilly cashes in too

 
• By Francesca Bruce

Bristol-Myers Squibb has completed its $7 billion acquisition of Amylin for $31 per share, paving the way for AstraZeneca to get in on the action. The UK firm has paid $3.2 billion to Amylin for an equal share in the profits generated by Amylin's diabetes drugs as part of an expanded diabetes alliance between the two firms. AstraZeneca also said it will also be buying the right to have a say in key strategic and financial decisions relating to the portfolio for $135 million. In June, Scrip highlighted the two pharmaceutical firms, which have worked together in diabetes since 2007, as prime contenders for the Amylin bid (scripintelligence.com, 27 June 2012). AstraZeneca's involvement in the BMS-Amylin deal was little surprise, as news of the acquisition broke, Scrip took a look at the events leading up to the deal (scripintelligence.com, 2 July 2012). Meanwhile, Lilly has upped its financial guidance after receiving $1.26 billion from its former partner Amylin for financial obligations relating to exenatide (Byetta, Bydureon). Lilly says it will use the money to develop its pipeline.

Bristol-Myers Squibb has completed its $7 billion acquisition of Amylin for $31 per share, paving the way for AstraZeneca to get in on the action. The UK firm has paid $3.2 billion to Amylin for an equal share in the profits generated by Amylin's diabetes drugs as part of an expanded diabetes alliance between the two firms. AstraZeneca also said it will also be buying the right to have a say in key strategic and financial decisions relating to the portfolio for $135 million. In June, Scrip highlighted the two pharmaceutical firms, which have worked together in diabetes since 2007, as prime contenders for the Amylin bid (scripintelligence.com, 27 June 2012). AstraZeneca's involvement in the BMS-Amylin deal was little surprise, as news of the acquisition broke, Scrip took a look at the events leading up to the deal (scripintelligence.com, 2 July 2012). Meanwhile, Lilly has upped its financial guidance after receiving $1.26 billion from its former partner Amylin for financial obligations relating to exenatide (Byetta, Bydureon). Lilly says it will use the money to develop its pipeline.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

More from Therapeutic Category

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?